NowPatient Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.1/10
Best for: an oral route if you will not self-inject
NowPatient falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Nothing is charged for the consultation at NowPatient; the medication is the whole bill. Because the out-of-pocket cost tracks brand list prices, an uninsured patient faces roughly $1,000-$1,350/mo. Access is to brand-name GLP-1s for weight management: Saxenda is on the menu, so is Mounjaro, and Wegovy comes as an injection and as an oral tablet. The company spans the US and UK, HQ Austin, TX.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to NowPatient
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
NowPatient at a glance
- Type
- GLP-1 telehealth provider
- Starting price
- $1069/mo
- What's included
- Medication · Consult
- FDA status
- No FDA warning letter on record
How NowPatient scores
Six columns, each one computed from something NowPatient has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
6.1/10$1069/month is 14% below the register median of $1249 for brand tirzepatide.
Effectiveness25%
10.0/10Dispenses liraglutide and semaglutide and tirzepatide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
2.5/10On the seller's own pages, no price appears until the medical intake is finished; a live video visit is required, which is slower but is the more careful intake.
Trust & Safety15%
4.0/10does not name a dispensing pharmacy; withholds price until after the intake. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.5/10The price covers medication, consult.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on NowPatient
Last checked July 2026- Re-read the price on file across 4 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with NowPatient involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1NowPatient does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
- 2The intake requires a live video visit with a clinician, which is more than most of the register asks and slower to complete.
- 3NowPatient does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult.
- Cheapest standing monthly prices on record: tirzepatide $1069, semaglutide $1349, liraglutide $1349. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether NowPatient serves your state cannot be confirmed from its site.
NowPatient support, as documented
- Hours
- Mon-Fri 8am-5pm EST (US); Mon-Fri 9am-6pm GMT (UK)
GLP-1 medications NowPatient offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off NowPatient's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Tirzepatide at $1069 a month, within the normal band around this register's $1249 median for the same drug and form
- The monthly figure covers medication and consult
- No FDA warning letter matched this operator when we searched our enforcement register
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
What NowPatient charges
The standing price at NowPatient is $1069/month. That sits above the middle of the market, which puts the burden on whatever else is in the package.
- Brand-name tirzepatide — $1069/month
- Brand-name semaglutide — $1349/month
- Brand-name semaglutide — $1349/month
- Brand-name liraglutide — $1349/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Check what is bundled before accepting it.
MangoRx dispenses semaglutide and tirzepatide from $299/month, which makes it the honest comparison to run before committing here.
What NowPatient dispenses
NowPatient prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. These are FDA-approved brand-name products rather than compounded preparations, which is the more expensive route and the one where what is in the vial has been reviewed.
What we could verify
NowPatient publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You need to bill insurance. Like most of this market, this is cash-pay.
Our read
NowPatient costs more than the middle of this market. If the extras it charges for are ones you would actually use, that is a defensible trade. If not, the same molecule is available for less.
The Bottom Line
NowPatient falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay NowPatient
Starting at $1069/month. Check today's price, then book the free consultation.
Where NowPatient is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this NowPatient review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See NowPatient's current pricing
Plans start at $1069/month. The free consultation is where you learn whether you qualify, and what it costs today.